3 unknown, 2 active not recruiting, 2 completed, 1 recruiting. 3 Phase 2, 2 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Recruiting 1, Unknown 1 |
| Not applicable | 2 | Active not recruiting 2 |
| Phase 4 | 1 | Unknown 1 |
Follow Immunologic Factors: new trials by email Literature Review of Immunologic Factors trials Research Report on Immunologic Factors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dual-Modality Immunotherapy for HPV Clearance (DUAL-HPV) Oral Immunomodulator, Vaginal Ovule, Standard Supportive Care - Human Papillomavirus Infection, Cervical Intraepithelial Neoplasia (CIN) | Not applicable | Active not recruiting | Dr. Lutfi Kirdar Kartal Training and Research Hospital | 76 | 2026-04-28 | 2026-07-29 |
| Identification of Immunomodulators Associated With Atrial Fibrillation Reporting: Analysis of the WHO Pharmacovigilance Database Immunomodulators with FDA approval on the 1st January 2023. - Atrial Fibrillation | Completed | University Hospital, Caen | 4000000 | 2022-08-01 | 2023-10-23 | |
| Comprehensive Assessment of Risks for Miscarriage. Markers of ultrasound, Immunologic factors, Serum factors - Spontaneous Abortion | Unknown | Orthogyn Medical Center, Bulgaria | 200 | 2020-06-20 | 2023-10-26 | |
| Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma Anti-PD-1 monoclonal antibody, Lenalidomide, Azacitidine - Relapsed/Refractory Peripheral T-cell Lymphoma | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 31 | 2020-01-01 | 2026-05-01 |
| Cryoablation for the Treatment of Metastatic Cancer Core Biopsy, Cryosurgery, Immunotherapeutic Agent - Metastatic Malignant Neoplasm | Not applicable | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2019-12-23 | 2026-08-06 |
| SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy SBRT, Immunological Agent, Immunological Factors - Lung Cancer Metastatic | Phase 2 | Unknown | The First Affiliated Hospital of Xiamen University | 48 | 2016-11-01 | 2016-11-29 |
| Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma MGN1703, Placebo - Advanced Colorectal Carcinoma | Phase 2 | Completed | Mologen AG | 59 | 2010-06-01 | 2014-06-20 |
| Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma Imiquimod 5% cream - Carcinoma, Basal Cell | Phase 4 | Unknown | University of Sao Paulo | 20 | 2008-12-01 | 2012-06-13 |
Abortion, Spontaneous (1) · Atrial Fibrillation (1) · Atypical Squamous Cells of the Cervix (1) · Carcinoma, Basal Cell (1) · Lung Neoplasms (1) · Lymphoma, T-Cell, Peripheral (1) · Neoplasm Metastasis (1) · Papillomavirus Infections (1) · Squamous Intraepithelial Lesions (1) · Uterine Cervical Dysplasia (1)
Dr. Lutfi Kirdar Kartal Training and Research Hospital (1) · M.D. Anderson Cancer Center (1) · Mologen AG (1) · Orthogyn Medical Center, Bulgaria (1) · The First Affiliated Hospital of Soochow University (1) · The First Affiliated Hospital of Xiamen University (1) · University Hospital, Caen (1) · University of Sao Paulo (1)
China (2) · France (2) · Austria (1) · Brazil (1) · Bulgaria (1) · Czechia (1) · Germany (1) · Russia (1) · Turkey (Türkiye) (1) · United Kingdom (1) · United States (1)
Alda L Tam (1) · Depei Wu, M.D (1) · Hans-Joachim Schmoll (1) · Petar N Ignatov, PhD (1)
PMID 23194937, PMID 24563870, PMID 25885553, PMID 26095785, PMID 27252448, PMID 31423933, PMID 32353110, PMID 41946548
2009 (1)